← Leaderboards
Samuel D Rabkin
Massachusetts General Hospital
$6,893,969
Attributed
$6,893,969
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $805.3K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,893,969 · 5
By mechanism
R01$4,436,572 · 2
P30$2,034,470 · 2
R21$422,927 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- E. Antonio Chiocca$34,514,665
- Robert L Martuza$21,256,149
- Pradeep G Bhide$8,542,290
- Xandra Owens Breakefield$30,735,276
- Fred H Hochberg$3,701,108
Others in their field
Top investigators on “Brain Neoplasms”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
- Walter John Curran · Thomas Jefferson University$98,312,615
- Gregory H Reaman · National Childhood Cancer Foundation$78,833,655
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- Robert H Vonderheide · University Of Pennsylvania$60,987,353
Research focus
Brain NeoplasmsBaseResponseProteinsGlioblastomaGenotypeTumorStem CellsTumorigenicModalityHsv VectorGrowthTherapy ResistantEvaluationRefractoryProgramsMalignant - DescriptorPhenotypeBrainPathway InteractionsFundingPrimary Brain NeoplasmsRecurrenceAntineoplastic Agents
Grant awards (25)
Targeting tumorigenic pathways in glioblastoma with oncolytic HSV$387,855
R01 · FY2023 · CA · contact PI
Targeting tumorigenic pathways in glioblastoma with oncolytic HSV$387,855
R01 · FY2022 · CA · contact PI
Targeting tumorigenic pathways in glioblastoma with oncolytic HSV$395,770
R01 · FY2021 · CA · contact PI
Targeting tumorigenic pathways in glioblastoma with oncolytic HSV$395,770
R01 · FY2020 · CA · contact PI
Targeting tumorigenic pathways in glioblastoma with oncolytic HSV$395,770
R01 · FY2019 · CA · contact PI
Targeting Tumorigenic Pathways in Glioblastoma with Oncolytic HSV$355,522
R01 · FY2016 · CA · contact PI
Targeting Tumorigenic Pathways in Glioblastoma with Oncolytic HSV$355,522
R01 · FY2015 · CA · contact PI
Targeting Tumorigenic Pathways in Glioblastoma with Oncolytic HSV$324,166
R01 · FY2014 · CA · contact PI
Interdepartmental Neuroscience Center$211,153
P30 · FY2014 · NS · contact PI
Targeting Tumorigenic Pathways in Glioblastoma with Oncolytic HSV$334,191
R01 · FY2013 · CA · contact PI
Interdepartmental Neuroscience Center$224,199
P30 · FY2013 · NS · contact PI
Selective Differentiation of Glioblastoma Stem Cells$213,471
R21 · FY2013 · CA · contact PI
Targeting Tumorigenic Pathways in Glioblastoma with Oncolytic HSV$356,356
R01 · FY2012 · CA · contact PI
Interdepartmental Neuroscience Center$239,483
P30 · FY2012 · NS · contact PI
Selective Differentiation of Glioblastoma Stem Cells$209,456
R21 · FY2012 · CA · contact PI
Interdepartmental Neuroscience Center$327,011
P30 · FY2010 · NS · contact PI
Interdepartmental Neuroscience Center$133,100
P30 · FY2009 · NS · contact PI
Core--Nucleic acid quantitation$201,875
P30 · FY2007 · NS · contact PI
Core--Nucleic acid quantitation$188,055
P30 · FY2006 · NS · contact PI
Core--Nucleic acid quantitation$177,442
P30 · FY2005 · NS
Core--Nucleic acid quantitation$168,491
P30 · FY2004 · NS
Core--Nucleic acid quantitation$163,661
P30 · FY2003 · NS
GENE DELIVERY TO THE CNS TO MODULATE EPILEPSY$260,863
R01 · FY2002 · NS
GENE DELIVERY TO THE CNS TO MODULATE EPILEPSY$224,119
R01 · FY2001 · NS
GENE DELIVERY TO THE CNS TO MODULATE EPILEPSY$262,813
R01 · FY2000 · NS